Aptevo Therapeutics Inc.
APVO Nasdaq
SEC CIK 1671584
Follow Aptevo Therapeutics
Weekly email: filings, results
Net income
−$6.5M
+13.2% vs same quarter last year
EPS, diluted
−$5.19
Operating cash flow
−$5.7M
+14.9% vs same quarter last year
Operating income
−$6.6M
+13.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$26M |
| FY24 | - | −$24.1M |
| FY23 | - | −$17.4M |
| FY22 | $3.1M | $8M |
| FY21 | $12.3M | −$28.5M |
| FY20 | $4.3M | −$17.8M |
| FY19 | $32.4M | −$40.4M |
| FY18 | $23.1M | −$53.7M |
| FY17 | $14.7M | $7M |
| FY16 | $10M | −$112.4M |
| FY15 | $33.6M | −$59.3M |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | - | - | - |
| FY22 | - | −919.7% | 257.8% |
| FY21 | - | −174.1% | −231.5% |
| FY20 | - | −638.1% | −411.9% |
| FY19 | 38.5% | −126.3% | −124.7% |
| FY18 | 51.4% | −224% | −232.8% |
| FY17 | 65.8% | −368.1% | 47.6% |
| FY16 | −24.9% | −1389.8% | −1125.8% |
| FY15 | 49.6% | −181.8% | −176.5% |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | −$21.1M |
| FY21 | −$22.4M |
| FY20 | −$29.4M |
| FY19 | −$42.5M |
| FY18 | −$52.4M |
| FY17 | −$43M |
| FY16 | −$39.4M |
| FY15 | −$50.3M |
| FY14 | - |
- Aptevo Therapeutics
- Healthcare median
Show the numbers
| Year | Aptevo Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | 257.8% | −80.4% |
| FY21 | −231.5% | −71.9% |
| FY20 | −411.9% | −62.2% |
| FY19 | −124.7% | −46.3% |
| FY18 | −232.8% | −49.6% |
| FY17 | 47.6% | −45.9% |
| FY16 | −1125.8% | −36% |
| FY15 | −176.5% | −38.4% |
| FY14 | - | −35.5% |